2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

Monday, December 14, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Treatment Considerations, Supportive Care, Biological Therapies, Transplantation, Bispecific Antibody Therapy, Chimeric Antigen Receptor, (CAR)-T Cell Therapies, Non-Biological Therapies, Chemotherapy, Artificial Intelligence (AI), Machine Learning, Clinical Practice (Health Services and Quality), Clinical Guidelines, Health Economics, Patient Safety, Practice Models, Quality Improvement, Quality of Care, Systems-Based Hematology, Diseases, Immunology, GVHD, Neutropenia, Lymphoid Malignancies, Lymphoid Leukemias, Lymphomas, Plasma Cell Disorders, Myeloid Malignancies, Acute Myeloid Malignancies, Chronic Myeloid Malignancies, Measurable Residual Disease, ALL, Research, AML, APL, MDS, MPN, CMML, Clinical Research, Clinical Trials, Health Outcomes Research, Health Disparities Research, Patient-Reported Outcomes, Real-World Evidence, Registries, Survivorship, Study Population, Human, Adult, Elderly
PAPER

6187 Expert interpretation of the 2025 European leukemianet (ELN) acute myeloid leukemia (AML) measurable residual disease (MRD) guideline: Results from an ELN-DAVID pilot testing project

Katie Lewis, MBBS PhD FRACP FRCPA, Jelena Jovanovic, PhD2, Nicolas Duployez, MD3, Gustav Orrsjö, MD4, Mariela Muraru5, Yishai Ofran, MD6, Luca Maurillo, MD7, Adriano Venditti, MD8, Albert Woelfler, MD9, Wing Kit Lam, MBBS, FRCPA10, Apostolia Papalexandri, MD11, Laura W Dillon, PhD12, Marcos Souza, MD13, Maura R.V. Ikoma-Colturato14, Malte Von Bonin, MD15, Artur Kowalik16, Francesco Mannelli17, Richard Dillon, MD18, Michael Heuser, MD19, Nicola Potter, PhD20
1 King's College London, London, United Kingdom
2 King's College London, London, United Kingdom
3 CHU Lille, Lille, France
4 Sahlgrenska University Hospital, Gothenburg, Sweden
5 West Midlands Genomics Laboratory, Birmingham Women’s Hospital, Birmingham, United Kingdom
6 Hebrew University, Jerusalem, West Jerusalem District, Israel, Shaare Zedek Medical Center, Jerusalem, Israel
7 Ospedale Santa Maria Goretti Pronto Soccorso, Latina, Italy, Sapienza University of Rome, Roma, Italy
8 University Tor Vergata, Rome, Italy
9 Medizinische Universität Graz, Graz, Austria
10 Tuen Mun Hospital, Tuen Mun, Hong Kong, Hong Kong
11 G. Papanikolaou Hospital, Thessaloniki, Greece
12 Fralin Biomedical Research Institute, Virginia Tech FBRI Cancer Research Center, Washington, United States
13 Hospital Amaral Carvalho, Sao Paulo, Brazil
14 Hospital Amaral Carvalho, Sao Paulo, Brazil
15 Technische Universität Dresden, Dresden, Germany, Universitätsklinikum Carl Gustav Carus, Dresden, Germany
16 Holy Cross Cancer Center, Kielce, Poland, Jan Kochanowski University, Kielce, Poland
17 Careggi University Hospital, Florence, Italy, University of Florence, Florence, Italy
18 Guy’s and St Thomas’ NHS Foundation Trust, London, United Kingdom, King's College London, London, United Kingdom
19 Martin-Luther-University Halle-Wittenberg, Halle, Germany, University Hospital Halle (Saale), Halle, Germany
20 King's College London, London, United Kingdom

Introduction

The European LeukemiaNet AML MRD Working Party (ELN-DAVID) is an international expert working group responsible for standardizing MRD assessment in AML. Recently the ELN-DAVID published the 2025 update for MRD in AML, providing a standardized framework for implementing the technical and clinical aspects of MRD assessment. Significantly, the latest iteration of this international guideline expanded on previous versions with the introduction of new concepts and updated testing thresholds, aligning with the latest clinical evidence.

One of the key objectives of ELN-DAVID is to promote education and training in AML MRD. To meet this objective a series of structured case-based molecular MRD training exercises were developed to be published on the ELN-DAVID website. These aim to assist individuals and diagnostic laboratories to standardize reporting and interpretation of the 2025 guideline update.

A pilot testing project was undertaken, whereby members of the ELN-DAVID working party completed the case-based training exercises to assess their usability, educational value and suitability for wider publication. Herein, we report the outcomes of this expert pilot testing project.

Methods

Thirteen structured case-based molecular MRD training exercises for NPM1 mutated AML were developed under the supervision of the ELN-DAVID qPCR sub-committee. Each case consisted of a case vignette and an excel worksheet containing complete technical testing data over multiple clinical timepoints. Respondents were tested on their knowledge of the technical requirements of testing, result interpretation, response criteria assignment and clinical recommendations. Answers were selected from a drop-down menu within the provided excel worksheet.  Fifteen members of the ELN-DAVID working party consented to participation in the pilot testing project and completed the training exercises between May and June 2026. Cumulative responses to the training exercises were reviewed and interrogated across multiple domains to determine the educational utility of the exercises, areas of concordance and discordance in expert interpretation of the 2025 AML MRD guideline and to improve delivery of the training exercises for a wider audience online.

Results

All 15 expert participants completed the 13 case-based exercises containing 1008 dropdown options, resulting in a total 15120 dropdown responses collected. The overall concordance amongst the expert test group was 83.3% (12590 correct responses). Responses were divided into 4 domains: technical requirements, result interpretation, response assignment and clinical recommendations. Overall concordance for the 4 domains was 86.5%, 79.0%, 89.0% and 79.3% respectively.

Critical decision timepoints, defined as clinical timepoints with potential to significantly alter patient management, demonstrated high concordance for post-course 2 peripheral blood assessment (90.9%) and end-of-treatment bone marrow assessment (83.3%).

There was overall lower concordance for responses pertaining to MRD relapse (70.8%) and low level MRD (MRD-LL, 64.1%) with clinical recommendations showing the most variability amongst expert respondents. Pre- and post-allogeneic HSCT assessment similarly showed below average concordance (78.9% and 76.5%). Over-interpretation (responses beyond the current guideline recommendations) was a common source of discordance in these scenarios. Clinical recommendations following a technically inadequate sample showed high variability amongst respondents (46.7% concordance). 

Conclusions

This pilot project is the first systematic evaluation of international AML MRD experts interpreting the 2025 ELN guideline. High levels of concordance were observed, particularly for well-established and clinically critical MRD assessment timepoints and sample types. Lower expert concordance was observed in cases with MRD-LL, MRD relapse, pre- and post-allogeneic HSCT and technically inadequate samples.  This reflects limitations in current clinical evidence, which does not allow for more defined guidance in the 2025 update.   

The results of this pilot testing project show that structured case-based training exercises are invaluable educational tools to promote standardized reporting and interpretation of the 2025 ELN-DAVID AML MRD guideline. In addition, it highlighted areas that future iterations of the guideline should ideally include to support further standardization of AML MRD assessments.  

Katie Lewis, MBBS PhD FRACP FRCPA: No relevant conflicts of interest to declare.